Antiarrhythmic drugs in pregnancy. (2nd December 2015)

• Record Type: Journal Article
• Authors: Wright, Jennifer M.; Page, Richard L.; Field, Michael E.
• Is Part Of: Expert review of cardiovascular therapy. Volume 13:Number 12(2015)
• Page Start: 1433
• Page End: 1444
• Publication Date: 2015-12-02
• Subjects: pregnancy -- arrhythmias -- antiarrhythmic drugs -- fetal outcomes -- beta-blocker -- adenosine -- flecainide -- sotalol -- digoxin; Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1586/14779072.2015.1107476
• Languages: English
• ISSNs: 1477-9072

Abstract

Abstract : The risk of arrhythmia development or recurrence is increased during pregnancy. For those arrhythmias that are unresponsive to conservative therapy, such as vagal maneuvers or life style interventions, or that present a higher risk to the mother or fetus, medical therapy may be necessary. In each case, the patient and provider must carefully consider the risks and benefits of a particular therapy. This requires an understanding of the data regarding the safety and efficacy of any particular drug, which in some cases may be extensive and in others quite limited. Fortunately, options exist for the treatment of arrhythmias during pregnancy.